STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst upgrades, a positive outlook on its STRO-004 pipeline, and a favorable price target increase. Despite short-term financial challenges, its long-term growth potential and innovative drug platform make it a compelling investment opportunity.
The technical indicators show mixed signals. The MACD is negative but contracting, suggesting a potential reversal. RSI is neutral at 71.616, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of R1: 25.458, indicating potential upward momentum.
Multiple analyst upgrades with significant price target increases (e.g., Deutsche Bank to $55, Wells Fargo to $27).
Positive sentiment around STRO-004's potential differentiation in efficacy and safety.
Revenue growth driven by collaborations with Astellas and Ipsen.
Strengthened cash position with $110 million share offering.
Short-term financial performance challenges with declining revenue, net income, and EPS in Q4
No recent significant hedge fund or insider trading activity.
Congress trading data unavailable.
Sutro Biopharma reported a revenue drop of -21.35% YoY to $11.65 million in Q4 2025, with net income down -35.45% YoY to -$46.76 million and EPS declining -39.07% YoY to -$5.35. However, FY25 revenue grew 65.2% to $102.48 million, driven by collaborations, and the company strengthened its cash position with a $110 million share offering.
Analysts are highly optimistic about Sutro Biopharma. Deutsche Bank, Wells Fargo, and H.C. Wainwright have all upgraded the stock with significant price target increases. The mean price target is $27.38, reflecting strong confidence in the company's future performance, particularly around its STRO-004 pipeline.
